GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » 5-Year EBITDA Growth Rate

Vidac Pharma Holding (STU:T9G) 5-Year EBITDA Growth Rate : 0.00% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding 5-Year EBITDA Growth Rate?

Vidac Pharma Holding's EBITDA per Share for the six months ended in Jun. 2024 was €-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Vidac Pharma Holding's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Vidac Pharma Holding's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vidac Pharma Holding's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's 5-Year EBITDA Growth Rate falls into.


;
;

Vidac Pharma Holding 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Vidac Pharma Holding  (STU:T9G) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Vidac Pharma Holding 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Vidac Pharma Holding Business Description

Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines